Active	Status	Sponsor type	Region	Phase	Filter
7 Active 16 Inactive 23 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes:- Show only changed items Enrollment:

Advanced Filters

7 Trials

Active Trials   

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
Shen, Feng
PLG001, NCT05668871: A Study of Danning Tablet in Patients With Polypoid Lesions of Gallbladder	Not yet recruiting	4	336	RoW	Danning Tablet, Biliflow (NPN 80073325, manufactured by Shanghai Hutchison Pharmaceuticals Limited)	Eastern Hepatobiliary Surgery Hospital	Polyps Gallbladder	08/24	11/24
NCT05862337: Anlotinib Hydrochloride Capsules Combined With Penpulimab Injection for the Treatment of Hepatocellular Carcinoma at High Risk of Recurrence.	Recruiting	3	480	RoW	Anlotinib hydrochloride capsules, Penpulimab injection, Anlotinib hydrochloride capsules -matching placebo, Penpulimab injection -matching placebo	Chia Tai Tianqing Pharmaceutical Group Co., Ltd.	Hepatocellular Carcinoma	08/24	12/26
TQB3454-III-01, NCT05987358: A Clinical Study of TQB3454 Tablets in the Treatment of Advanced Biliary Carcinoma.	Not yet recruiting	3	165	RoW	TQB3454 tablets, TQB3454 tablets matching placebo	Chia Tai Tianqing Pharmaceutical Group Co., Ltd.	Biliary Carcinoma	12/26	12/26
NCT05913336: A Study of Remimazolam Tosilate for Prolonged Sedation in the ICU	Recruiting	1/2	20	RoW	Remimazolam Tosilate	Jiangsu HengRui Medicine Co., Ltd.	Sedation in the ICU	11/23	11/23
TQB2102-Ib/II-01, NCT06431490: A Study of TQB2102 for Injection in the Treatment of HER2-positive Biliary Tract Cancer	Recruiting	1/2	103	RoW	TQB2102 for injection	Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.	Biliary Tract Cancer	05/25	12/25
NCT05292443: Therapeutic ResistAnce and Clonal Evolution Assessed With Liquid Biopsy in ICIs Treated Primary Liver Cancer	Withdrawn	N/A	300	RoW	Observation	Geneplus-Beijing Co. Ltd., Eastern Hepatobiliary Surgery Hospital	Primary Liver Cancer, Hepatocellular Carcinoma, Intrahepatic Cholangiocarcinoma, Combined Hepatocellular-cholangiocarcinoma	03/23	03/23
Bao, Leilei
TQB2102-Ib/II-01, NCT06431490: A Study of TQB2102 for Injection in the Treatment of HER2-positive Biliary Tract Cancer	Recruiting	1/2	103	RoW	TQB2102 for injection	Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.	Biliary Tract Cancer	05/25	12/25